Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Wednesday, April 25, 2018

Protein That Dilates Blood Vessels Found

I could easily see this being used to deliver more blood to the brain post ischemic stroke as long as the criteria assuring safety and not causing brain bleeds is established. But that would assume we have some stroke leadership following through to see it to completion. We have NO stroke leadership so nothing will happen. Incompetence reigns in the stroke world until we get stroke survivors running things.  The leaders and boards of directors of the ASA, NSA and WSO should either step down or be fired. I could see this possibly helping to stop pericytes from strangling capillaries post-stroke, but no one will follow that idea up. 

Protein That Dilates Blood Vessels Found

Americans die of heart or cardiovascular disease at an alarming rate. In fact, heart attacks, strokes and related diseases will kill an estimated 610,000 Americans this year alone. Some medications help, but to better tackle this problem, researchers need to know exactly how the heart and blood vessels stay healthy in the first place.

Now, scientists at The Scripps Research Institute have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.

“It has been known for decades that blood vessels sense changes in blood flow rate, and this information is crucial in regulating blood vessel dilation and controlling vascular tone,” says Ardem Patapoutian, PhD, Scripps Research professor, Howard Hughes Medical Institute investigator and senior author of the study published today in the journal Cell.

Indeed, flow-mediated dilation (FMD) is a non-invasive clinical test that informs doctors about the health of the vascular system. A compromised FMD is a precursor to a wide array of vascular diseases such as hypertension and atherosclerosis.

“Despite the importance of this process, the molecules involved within arteries to sense blood flow have remained unknown,” Patapoutian says.

Patapoutian and first author Jie Xu, PhD, a postdoctoral fellow in the lab, and now an independent scientist at the Genomics Institute of the Novartis Research Foundation (GNF), led the project to find GPR68 and determine how it works. The team started by designing a machine that uses turbulent movement of liquid to stand in for blood flow in blood vessels. This machine uses 384 pistons that move the fluid up and down over a bed of cells, placed in 384 wells on a plate. This motion simulates how blood would put pressure on those cells.
To test how cells respond to sheer stress, the researchers designed a machine that uses turbulent movement of liquid to stand in for blood flow in blood vessels. (Photo from Ardem Patapoutian and Jie Xu)

The researchers put this machine to work testing a series of cell lines, some of which had mutations that led to an overexpression of proteins potentially linked to pressure sensing. The researchers then performed a screen, knocking down the expression of different candidate genes in each of the 384 wells, and tested if that gene is required for responding to the machine’s turbulent pressure.

The tests pointed the researchers to GPR68, which the authors showed works as a sensor of mechanical stimulation. Further experiments suggested that GPR68 is essential for FMD.  “In a model organism, this protein is essential for sensing blood flow, and the proper functioning of the vascular system,” says Patapoutian.

When arterioles can’t dilate properly, the body has fewer options for lowering blood pressure in people with hypertension or getting blood through clogged vessels in cases of atherosclerosis.

“Future work will explore the role of GPR68 in clinically relevant cardiovascular diseases,” Patapoutian says. “We are also exploring the possibility of using small molecules to modulate the function of GPR68, as such molecules could be beneficial in the clinic.” 

This article has been republished from materials provided by The Scripps. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:
Xu, J., Mathur, J., Vessières, E., Hammack, S., Nonomura, K., Favre, J., . . . Patapoutian, A. (2018). GPR68 Senses Flow and Is Essential for Vascular Physiology. Cell, 173(3). doi:10.1016/j.cell.2018.03.076

No comments:

Post a Comment